← Back to all trials
Completed
NCT05648734
Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis
Conditions: Post-COVID-19 Syndrome, Lung Fibrosis
Sex: All
Ages: 18 Years – N/A
Enrollment: 200
Sponsor: Mansoura University
Location: Egypt
Summary
In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.
Eligibility Criteria
Inclusion Criteria:Adult patients who have COVID-19 pneumonia confirmed either by RT-PCR or radiologically by CT scan and according to WHO severity classification are (Moderate, severe, or critical) and has received either: Corticosteroids alone.Corticosteroids in combination with Colchicine.Corticosteroids in combination with Pirfenidone.Corticosteroids in combination with Colchicine and Pirfenidone.Exclusion Criteria:None COVID-19 pneumonia.Patients with previous parenchymal lung disease.Patients receiving anti-fibrotic or anti-inflammatory drugs due to other chronic disease.Patients who received anti-fibrotic and or ant inflammatory drugs for duration and or doses less than presumed or those who reported noncompliance to treatment.Patients with uncontrolled comorbidities.Patients who develop severe intolerable side effects or derangement of liver enzymes more than 5 folds.Pregnant ladies with COVID-19 pneumonia.
Source: ClinicalTrials.gov (NCT05648734). StuddyBuddy aggregates publicly available trial information.
